What does the latest wave of FDA approvals tell us about where specialty medicines are heading? … Recent approvals across rare neuromuscular disease, primary immunodeficiency, and oncology point to a common direction: greater therapeutic precision, increasingly specialized patient populations, and treatment approaches designed around specific biological targets or disease mechanisms.
From a muscle-targeted approach in spinal muscular atrophy to selective immune modulation in APDS and receptor-targeted radioligand therapy in GEP-NETs, three recent FDA approvals illustrate how therapeutic innovation is creating new treatment possibilities across distinct areas of medicine.
| Drug Name | Company | Active Ingredient | Disease / Indication | FDA Approval Date |
|---|---|---|---|---|
| ISEMBYLD | Scholar Rock | Apitegromab-mstn | Spinal muscular atrophy (SMA) | September 11, 2026 |
| Joenja | Pharming | Leniolisib | Activated PI3Kδ syndrome (APDS) | September 11, 2026 |
| BEXLUTRY | Curium | Lutetium Lu 177 dotatate | SSTR-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) | September 14, 2026 |
Here’s a closer look at the three recent FDA actions and what they could mean for the specialty medicines landscape.
Scholar Rock’s ISEMBYLD Wins FDA Approval as First Muscle-Targeted Treatment for SMA
The U.S. Food and Drug Administration has approved ISEMBYLD (apitegromab-mstn) from Scholar Rock for treating spinal muscular atrophy (SMA) in adults and pediatric patients aged two years and older who are currently receiving an SMN2-targeted treatment. FDA describes SMA as a rare neuromuscular disease involving motor neuron loss, muscle weakness, and atrophy.
ISEMBYLD represents a distinct therapeutic approach within the SMA treatment landscape. Existing SMN2-targeted therapies address the underlying motor-neuron survival pathway, while ISEMBYLD directly targets muscle loss. FDA describes it as the first approved SMA therapy to directly target muscle loss and notes that it is intended for use in patients receiving an SMN2-targeted treatment.
The approval was supported by the Phase 3 SAPPHIRE study, a randomized, placebo-controlled trial evaluating ISEMBYLD in people with SMA receiving an SMN2-targeted therapy. The study demonstrated improvement in motor function after one year compared with placebo. At the recommended 10 mg/kg dose, ISEMBYLD produced a 2.2-point improvement in the Hammersmith Functional Motor Scale Expanded (HFMSE) score versus placebo at one year.
For Scholar Rock, the approval also represents a significant commercial transition from development to market launch. The company has stated that its U.S. commercial organization is working with physicians, SMA care teams, and payers, while its patient-support organization is preparing assistance for patients and caregivers.
Following the approval, Scholar Rock was also granted a Rare Pediatric Disease Priority Review Voucher, which can provide priority review for a future marketing application.
Pharming’s Joenja Expands FDA-Approved Treatment to Children With APDS
FDA has approved an expanded indication for Joenja (leniolisib), Pharming’s selective PI3Kδ inhibitor, which is now the first FDA-approved treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS) who weigh at least 27 kg.
The action extends the original March 2023 FDA approval of Joenja for treating adults and pediatric patients aged 12 years and older with APDS. This action is represented as an expanded indication, rather than a first-time approval.
APDS is a rare genetic disease that affects the immune system. Patients can experience recurrent infections, enlarged lymph nodes and other organs, and other immune dysregulation complications. Pharming’s newly approved pediatric dosing approach is based on body weight, rather than age. For eligible children aged 4-11 years weighing at least 27 kg can take Joenja at 40 mg, 50 mg, and 70 mg twice daily, depending on body weight.
The new FDA approval relied on a multinational Phase 3 clinical trial in children with APDS ages 4 to 11 years. The study evaluated change over 12 weeks of treatment in lymphadenopathy and naive B-cell levels, with FDA citing the safety profile as similar to what was observed previously.
The expanded indication also illustrates how extending an existing therapy into a younger population can create a new commercial and access opportunity. Pharming has stated that the newly authorized doses are expected to become available to eligible U.S. pediatric patients through its existing specialty distribution and patient-support infrastructure.
Curium’s BEXLUTRY Receives FDA Approval for SSTR-Positive GEP-NETs
FDA has approved BEXLUTRY (lutetium Lu 177 dotatate injection) from Curium for the treatment of adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut and hindgut neuroendocrine tumors.
BEXLUTRY is a radioligand therapy designed to deliver targeted radiation to tumors by binding to somatostatin receptors present on GEP-NETs. The product was approved under the FDA’s 505(b)(2) pathway based on published evidence and targeted bridging data to establish similarity to an already approved lutetium Lu 177 dotatate radiopharmaceutical therapy.
The approval marks Curium’s entry into FDA-approved oncology therapeutics and expands their role beyond its established nuclear medicine and diagnostic capabilities. According to Curium, BEXLUTRY is its first FDA-approved radioligand therapy.
The commercial implications extend beyond the therapy itself. Radioligand therapy requires specialized treatment infrastructure, radiation-safety processes, trained healthcare professionals and coordinated site-of-care operations. Curium has emphasized supply reliability, scheduling support and site readiness as priorities for the launch.
This makes BEXLUTRY a notable example of how commercializing targeted therapies can depend not only on clinical and regulatory differentiation, but also on the readiness of the broader healthcare delivery ecosystem.
IeB Perspective
Regulatory Approval is the Beginning of the Commercial Strategy, Not the End.
The above-mentioned three examples demonstrate highly specialized therapies. While these therapies address very different diseases and use different mechanisms, their approvals highlight a broader trend in the specialty medicines space—innovation is being defined not only by whether a therapy reaches regulatory approval, but how precisely it addresses disease biology, which patient populations it can target, and how effectively healthcare systems can adopt that innovation.
